Medindia

X

Three Industry Veterans Join Ascension Orthopedics

Saturday, June 14, 2008 General News J E 4
Advertisement
AUSTIN, Texas, June 13 Ascension Orthopedics, Inc., aleader in orthopedic extremity implants, announces the hiring of threeorthopedic executives, William F. Warrender, Jr., John F. Walters and David C.Furr, as new Senior Vice Presidents. Their extensive background and experiencewill make a substantial contribution to the future growth of Ascension.

Bill Warrender joined Ascension on April 14 as Senior Vice President ofGlobal Sales. He brings more than 25 years of sales, marketing and generalmanagement experience to the executive team. Warrender was most recently basedin Pennsylvania as President of Medartis, Inc. and has held managementpositions with Encore Orthopedics, Smith & Nephew, and Zimmer, among others."Bill will contribute a valuable 'can-do' spirit to our sales team," statesAndrew J. Miclot, President and CEO of Ascension. Warrender has a B.S. inMarketing and Management from LaSalle University and an M.B.A. in Managementand Finance from the University of Notre Dame.

John Walters assumed the role of Senior Vice President of Global Marketingon June 2. He has been active in the orthopedic medical device field for over20 years, having high-level positions at market-leading corporations includingDepuy, Johnson & Johnson and Wright Medical Technologies. "John has acombination of marketing, development and financial experience in orthopedicsthat will be an important asset as we work to reposition ourselves and expandwithin the extremities market," says Miclot. Walters received his B.S. degreein Biology and his M.B.A. in Management and Finance from the University ofArizona.

David Furr also joined the executive team on June 2, as Senior VicePresident of Quality Assurance, Regulatory Affairs and Clinical Affairs. Priorto accepting this new role at Ascension, Furr was president and principal ofFDC Services, LLC, a consulting firm specializing in quality, regulatory andclinical issues for the orthopedic, medical device and pharmaceuticalindustries. "He brings the kind of seasoned leadership that will be requiredas we continue to branch out in a worldwide market where regulationsconstantly evolve," explains Miclot. During his nearly 30 years of experience,Furr has also held senior positions at Boston Scientific, Bristol-MyersSquibb/Zimmer and Greer Laboratories. He holds a B.S. degree in Chemistry fromTexas State University and an M.S. degree in Quality Assurance and RegulatoryAffairs from the Temple University School of Pharmacy.

Ascension Orthopedics secured $21 million in a Series D financing inJanuary 2008. Frazier Healthcare Ventures lead this round of funding as themajority investor. "We appreciate Frazier's investment in Ascension. Theircommitment to our company has enabled us to hire these talented executives,"said Miclot.

About Ascension Orthopedics, Inc.

Ascension Orthopedics started in Austin, Texas in 1996. In 2001, Ascensionreceived FDA PMA approval for its first product, an innovative pyrolyticcarbon total joint replacement for the MCP (Knuckle) joint of the hand. Thecompany has since increased its joint replacement product line to includeimplants for the shoulder, elbow, wrist, fingers and toes. AscensionOrthopedics is dedicated to the development of orthopedic implants for upperand lower extremities. Ascension's mission is to help surgeons treat patientssuffering from pain and dysfunction, by developing state of the art orthopedicproducts. Ascension Orthopedics sells products in the United States and inmore than 20 foreign countries worldwide. For further information, pleasevisit http://www.ascensionortho.com/.

About Frazier Healthcare

Investing since 1991, Frazier Healthcare Ventures is one of the nation'sleading providers of venture and growth equity capital to emerging biopharma,medical device and healthcare service companies. With more then $1.8 billionunder management, Frazier Hea
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Pharmaceutical Competitive Intelligence Excellence...
S
Haemacure to Present at the BioInternational Conve...